Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 8, 2018
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , April 30, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , April 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
View HTML
Toggle Summary AGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization's Board of Directors
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it
View HTML
Toggle Summary AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017
GAINESVILLE, Fla., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the
View HTML
Toggle Summary AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 7, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today
View HTML
Visionary science for life changing cures.